Actively Recruiting
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Led by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. · Updated on 2025-07-23
36
Participants Needed
3
Research Sites
75 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a phase Ia clinical study evaluating H1710 for Injection in Participants with advanced solid tumors.
CONDITIONS
Official Title
A Clinical Study Evaluating H1710 for Injection in Participants With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years, any gender, ethnicity, financial or educational background
- Signed informed consent before screening
- Histologically or cytologically confirmed advanced solid tumors
- Failed standard treatment, have no standard treatment, or are intolerant/not suitable for standard treatment
- Measurable or evaluable lesions per RECIST version 1.1
- ECOG performance status of 0 or 1
- Predicted life expectancy of at least 3 months
- Adequate bone marrow and organ function within 7 days before first dose of H1710
You will not qualify if you...
- Malignant tumor lesions at high risk of bleeding as judged by investigator
- Active significant bleeding or high risk of hemorrhage
- Major surgery, interventional therapy, or significant trauma within 28 days before first dose
- Elective surgery planned during the trial
- Spinal, epidural, or loco-regional anesthesia within 24 hours before first dose
- Primary brain tumors or active brain/meningeal metastases with symptoms requiring intervention within 28 days
- Poorly controlled pleural, pericardial effusion, or ascites needing repeated drainage
- Anti-tumor therapy within 28 days before first dose, except as judged by investigators
- Another active invasive malignancy, except as judged by investigators
- Symptomatic congestive heart failure, unstable angina, sinus bradycardia, uncontrolled hypertension, ongoing arrhythmia
- Uncontrolled diabetes
- History of significant interstitial lung disease or pneumonia
- Myocardial infarction within 6 months, coronary stenting within 12 months, or arterial thromboembolic event within 3 months before first dose
- Live attenuated vaccine within 28 days before first dose or planned during study unless approved
- HIV infection or positive, active Hepatitis B or C infection except as judged by investigators
- Active bacterial, fungal, or viral infections requiring antibiotics within 14 days before first dose
- Unresolved adverse events from prior anti-tumor therapy above Grade 1 except certain low-risk toxicities
- Participation in other clinical studies within 28 days or current participation in other investigational trials
- Pregnant or lactating females or those intending pregnancy during or within 6 months after trial
- Refusal to use reliable birth control during trial and 6 months after
- Clinically significant psychiatric, social, or medical conditions affecting safety or protocol adherence
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Beijing Cancer Hospital
Beijing, China, 100142
Actively Recruiting
2
Peking University Shougang Hospital
Beijing, China, 100144
Actively Recruiting
3
Shanghai East Hospital
Shanghai, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here